Long Non-Coding RNAs in Thyroid Cancer
DOI:
https://doi.org/10.63682/jns.v14i17S.5807Abstract
Background: Accurate preoperative differentiation between benign and malignant thyroid nodules remains a clinical challenge, particularly in cases with indeterminate cytology. Conventional diagnostic tools such as ultrasound and fine-needle aspiration cytology have limited diagnostic accuracy in a subset of patients. Long non-coding RNAs, including Nuclear Enriched Abundant Transcript 1 (NEAT1), have emerged as potential molecular biomarkers in various malignancies, including thyroid cancer.
Method: This observational cross-sectional study included sixty adult participants divided into three equal groups: patients with malignant thyroid nodules, patients with benign thyroid nodules, and healthy controls. Serum samples were collected from all participants. NEAT1 expression levels were quantified using quantitative real-time polymerase chain reaction and analyzed in serum. Statistical analysis and receiver operating characteristic (ROC) curve analysis were performed to assess the diagnostic performance of NEAT1 expression.
Result: NEAT1 expression levels in serum was significantly higher in patients with malignant thyroid nodules compared with benign nodules and controls (p < 0.001). Serum NEAT1 expression showed a strong positive correlation. ROC curve analysis demonstrated high diagnostic accuracy of NEAT1 expression.
Conclusion: NEAT1 is significantly upregulated in malignant thyroid nodules and demonstrates strong diagnostic performance. Circulating NEAT1 may serve as a promising non-invasive molecular biomarker to complement conventional diagnostic tools in the preoperative evaluation of thyroid nodules.
Downloads
References
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
2. Bray, F., Laversanne, M., Weiderpass, E., & Soerjomataram, I. (2024). The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 130(1), 9–16. https://doi.org/10.1002/cncr.34853
3. Ali, S. Z., Cibas, E. S., & The Bethesda System for Reporting Thyroid Cytopathology Committee. (2023). The Bethesda system for reporting thyroid cytopathology: Definitions, criteria, and explanatory notes (3rd ed.). Springer.
4. Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., et al. (2016). 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 26(1), 1–133. https://doi.org/10.1089/thy.2015.0020
5. Kung, J. T. Y., Colognori, D., & Lee, J. T. (2013). Long noncoding RNAs: Past, present, and future. Genetics, 193(3), 651–669. https://doi.org/10.1534/genetics.112.146704
6. Derrien, T., Johnson, R., Bussotti, G., Tanzer, A., Djebali, S., Tilgner, H., et al. (2012). The GENCODE v7 catalog of human long noncoding RNAs. Genome Research, 22(9), 1775–1789. https://doi.org/10.1101/gr.132159.111
7. Schwarzenbach, H., Nishida, N., Calin, G. A., & Pantel, K. (2014). Clinical relevance of circulating cell-free nucleic acids in cancer. Nature Reviews Clinical Oncology, 11(3), 145–156. https://doi.org/10.1038/nrclinonc.2014.5
8. Ghafouri-Fard, S., & Taheri, M. (2019). Nuclear enriched abundant transcript 1 (NEAT1): A long non-coding RNA with diverse functions in cancer. Biomedicine & Pharmacotherapy, 111, 51–59. https://doi.org/10.1016/j.biopha.2018.12.070
9. Xia, F., Chen, Y., Jiang, B., Bai, N., Li, X., & Xu, Y. (2019). Long noncoding RNA NEAT1 promotes papillary thyroid cancer progression. Cancer Cell International, 19, 44. https://doi.org/10.1186/s12935-019-0756-1
10. Li, X., Wang, Z., Zhang, Z., Li, Y., Xu, Q., & Li, S. (2016). Long non-coding RNA NEAT1 promotes thyroid carcinoma progression through regulation of miR-214. International Journal of Oncology, 48(4), 1704–1712. https://doi.org/10.3892/ijo.2016.3373
11. Zhong, Y., Gao, D., He, S., Shuai, C., Peng, S., & Wang, J. (2019). NEAT1 promotes papillary thyroid carcinoma progression. OncoTargets and Therapy, 12, 8015–8026. https://doi.org/10.2147/OTT.S215821
12. Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻ΔΔCT method. Methods, 25(4), 402–408. https://doi.org/10.1006/meth.2001.1262
13. Kitahara, C. M., & Schneider, A. B. (2022). Epidemiology of thyroid cancer. Cancer Epidemiology, Biomarkers & Prevention, 31(7), 1284–1297. https://doi.org/10.1158/1055-9965.EPI-21-1440
14. Al-Hakami, H. A., Alqahtani, R., Alahmadi, A., Alsharif, A., Alzahrani, A., & Alzahrani, A. (2020). Patterns and risk factors of thyroid cancer in Saudi Arabia. Journal of Thyroid Research, 2020, 8423146. https://doi.org/10.1155/2020/8423146
15. Ramadan, R., Mohamed, A., & El-Sayed, M. (2021). Clinicopathological characteristics of thyroid cancer in an Egyptian population. Endocrine Practice, 27(4), 345–352.
16. Zhao, L., Sun, H., Kong, H., Chen, Z., Chen, B., & Zhou, M. (2020). Differential expression of NEAT1, miR-9 and miR-124 in thyroid nodules. Molecular Medicine Reports, 21(3), 1237–1246. https://doi.org/10.3892/mmr.2020.10923.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
